InvestorsHub Logo

H2R

Followers 42
Posts 2156
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Wednesday, 10/25/2017 10:40:45 AM

Wednesday, October 25, 2017 10:40:45 AM

Post# of 4817
SmithOnStocks on ATRS

https://smithonstocks.com/antares-approval-of-xyosted-is-a-matter-of-when-not-if-atrs-2-12-buy/

It's a subscription site, so I don't want to cut&paste the whole article. One main point is that the pharmacokinetic parameters are within other products on the market ... it's actually better than other products from the FDA noted perspective.

(Again, see http://www.smsna.org/scottsdale2016/presentations/131.pdf)

Still hmmm on this one from the FDA.